2Skyler JS. Diabetes mellitus: pathogenesis and treatment strategies.J Med Chem 2004; 47:4113-7.
3American Diabetes Association and National Institutes of Diabetes Digestive and Kidney Diseases. The prevention or delay of type 2 diabetes. Diabetes Care 2002; 25: 742-9.
4Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel N J, Comstock JP, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type I1 diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type Ⅱ Diabetes. Diabetes Care 1995: 18: 1113-23.
5Ohkubo Y, Kishikawa H, Araki E, Miyata T, lsami S, Motoyoshi S, etal. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pratt 1995; 28: 103-17.
6Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-86.
7DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303.
8Gaster B, Hirsch lB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998;158: 134-40.
9Rang HP, Dale MM. The endocrine system pharmacology, UK:Longman Group; 1991. p504-8.
10Xie JT, Mehendale S, Yuan CS. Ginseng and diabetes. Am J Chin Med 2005; 33:397-404.
